Patterns of minimal residual disease after high dose therapy in myeloma - A comparison of allografting and autografting.

被引：0
|
作者：
Haynes, AP
Carter, GI
Owen, R
Davis, F
Byrne, J
Bybee, A
Samsom, D
Morgan, GJ
Russell, NH
机构：
[1] CITY HOSP NOTTINGHAM,DEPT HAEMATOL,NOTTINGHAM,ENGLAND
[2] LEEDS GEN INFIRM,LEEDS,W YORKSHIRE,ENGLAND
[3] HAMMERSMITH HOSP,LONDON,ENGLAND
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：995 / 995
页数：1
相关论文
共 50 条
  • [21] MAINTENANCE THERAPY WITH BORTEZOMIB IN PATIENTS WITH MULTIPLE MYELOMA (MM) AFTER ASCT AND MINIMAL RESIDUAL DISEASE (MRD)
    Solovev, M.
    Mendeleeva, L.
    Pokrovskaya, O.
    Gemdzhian, E.
    Galtseva, I.
    Davydova, J.
    Firsova, M.
    Nareyko, M.
    Abramova, T.
    Savchenko, V.
    HAEMATOLOGICA, 2017, 102 : 531 - 531
  • [22] Impact of minimal residual disease detection after treatment of multiple myeloma
    Szendrei Tamas
    Plander Mark
    Szabo Zsuzsanna
    Kereskai Laszlo
    Kajtar Bela
    Papp Gergely
    Ivanyi Janos Laszlo
    ORVOSI HETILAP, 2019, 160 (13) : 502 - 508
  • [23] Multiple myeloma: Maintenance therapy after autologous stem cell transplantation, depending on minimal residual disease
    Solovyev, M. V.
    Mendeleeva, L. P.
    Pokrovskaya, O. S.
    Nareyko, M. V.
    Firsova, M. V.
    Galtseva, I. V.
    Davydova, Yu. O.
    Kapranov, N. M.
    Kuzmina, L. A.
    Gemdzhian, E. G.
    Savchenko, V. G.
    TERAPEVTICHESKII ARKHIV, 2017, 89 (07) : 25 - 31
  • [24] Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma
    Nahi, Hareth
    Afram, Gabriel
    Uttervall, Katarina
    Lockmer, Sandra
    Tatting, Love
    Gahrton, Gosta
    Kashif, Muhammad
    Alici, Evren
    Stromberg, Olga
    Klimkowska, Monika
    Lund, Johan
    CANCER MEDICINE, 2023, 12 (22): : 20736 - 20744
  • [25] Impact of Minimal Residual Disease in High and Standard Risk Multiple Myeloma
    Schinke, Carolina
    Deshpande, Shayu
    Mitchell, Alan
    Faham, Malek
    Patel, Purvi
    Thanendrarajan, Sharmilan
    Mohan, Meera
    Mathur, Pankaj
    Matin, Aasiya
    Radhakrishnar, Muthukumar
    Tytarenko, Ruslana
    Stephens, Owen W.
    van Rhee, Frits
    Zangari, Maurizio
    Jethava, Yogesh
    Petty, Nathan
    Alapat, Daisy V.
    Johnson, Sarah K.
    Epstein, Joshua
    Barlogie, Bart
    Davies, Faith E.
    Heuck, Christoph
    Hoering, Antje
    Weinhold, Niels
    Morgan, Gareth J.
    BLOOD, 2015, 126 (23)
  • [26] POINT Should minimal residual disease negativity be the end point of myeloma therapy?
    Anderson, Kenneth C.
    BLOOD ADVANCES, 2017, 1 (08) : 517 - 521
  • [27] Bone density after high dose therapy for myeloma
    Jacob, A
    Murray, JA
    Holmes, J
    Boivin, CM
    BRITISH JOURNAL OF HAEMATOLOGY, 1999, 105 : 83 - 83
  • [28] Genetically Undetectable and Negative Minimal Residual Disease after Induction Therapy Are Equally Crucial for Survival in Multiple Myeloma
    Cui, Jian
    Liu, Jiahui
    Fan, Huishou
    Qiu, Lugui
    Anderson, Kenneth C.
    An, Gang
    BLOOD, 2022, 140 : 7185 - 7186
  • [29] Genetically undetectable and negative minimal residual disease after induction therapy are equally important for survival in multiple myeloma
    Cui, Jian
    Liu, Jiahui
    Fan, Huishou
    Yan, Wenqiang
    Xu, Jingyu
    Du, Chenxing
    Deng, Shuhui
    Qiu, Lugui
    An, Gang
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S59 - S60
  • [30] High-dose therapy with peripheral blood progenitor cell (PBPC) autografting in multiple myeloma (MM)
    Goldschmidt, H
    Hegenbart, U
    Wallmeier, M
    Fruehauf, S
    Hohaus, S
    Wannenmacher, M
    Haas, R
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 404 - 404
12345